Tecentriq (Atezolizumab)
atezolizumab 840 mg/14 mL injection, 14 mL vial · INJECTION · PBS code 11940K
STREAMLINEDWhat it costs
AU$4723.15 PBS-determined price per pack
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2020-04-01.
- • Repeats: 3.
- • PBS program: IN.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Locally advanced or metastatic non-small cell lung cancer
Initial treatment - 4 weekly treatment regimen
Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for this condition; AND
Patient must have a WHO performance status of 0 or 1; AND
The treatment must be the sole PBS-subsidised therapy for this condition; AND
The condition must have progressed on or after prior platinum based chemotherapy; or
The condition must have progressed after treatment with a prior targeted therapy PBS-listed for this condition.
Sponsor: Roche Products Pty Ltd ABN 70 000 132 865
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.